Clinical Trial Update: A Study to Explore the Long-Term Safety and Efficacy of Fremanezumab (TEV-48125) for the Prevention of Cluster Headache [Phase 3]

View source ↗

Summary

Phase 3 trial update for fremanezumab in preventing cluster headache; study terminated with posted results in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cluster Headache

Drugs mentioned

• Fremanezumab (fremanezumab)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Cluster Headache | Phase 3 | Status: TERMINATED | Results posted: 2020-05-06